Continued strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea

Allschwil, Switzerland, March 11, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that the continued strong sales performance of the antifungal Cresemba® (isavuconazole) by its license partner Pfizer Inc. in the Asia Pacific region and China exceeded the sales threshold triggering a USD 1.25 million milestone payment. David Veitch, Basilea’s

Related Keywords

United States ,Allschwil ,Switzerland General ,Switzerland ,Australia ,Basilea ,Basel Stadt ,Iceland ,China ,Japan ,Liechtenstein ,Norway ,Swiss ,David Veitch ,Asia Pacific ,Nils Schr ,Isavuconazole Cresemba ,Swiss Exchange ,Pfizer Inc ,Head Of Corporate Communications Investor Relations ,Basilea Pharmaceutica Ltd ,European Union ,Pharmaceutica Ltd ,Chief Executive Officer ,Corporate Communications ,Public Assessment Report ,